Skip to content
DataLookout
Start free
Menu

VELOTANCT07321873

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 12 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Final enrollment: 157 participants (planned 240)
    • Site details revised at 75 of 75 sites
  2. Study sites: 73 to 75
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 7 of 7 entries
  3. Study sites: 72 to 73v10
  4. Trial sites expanded: 68 → 72 locationsv9
  5. Trial sites expanded: 63 → 68 locationsv8
  6. Trial sites expanded: 40 → 63 locations
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: 9 to 7
    v7
  7. Trial sites expanded: 19 → 40 locationsv6
  8. Study sites: 10 to 19v5
  9. Study sites: 4 to 10v4
  10. Start date changed from estimate of Jan 30, 2026 to Jan 15, 2026
    • Secondary endpoints revised (9)
    • Study title shortened, about 5 words
    v3
  11. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 4
    v2
  12. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of Participants who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16
Timeframe: Week 16

Secondary (7)

Proportion of Participants Who Achieved Psoriatic Area and Severity Index (PASI) 75 Response at Week 16 Among Participants with Baseline Body Surface Area (BSA) Greater Than or Equal to (>=) 3 Percent (%)
Proportion of Participants Who Achieved PASI 90 Response at Week 16 Among Participants with Baseline BSA >=3%
Proportion of Participants Who Achieved PASI 100 Response at Week 16 Among Participants with Baseline BSA >=3%
Proportion of Participants who Achieved an ACR 20 Response at Week 16
Proportion of Participants who Achieved an ACR 70 Response at Week 16
Show 2 moreShow less
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score At Week 16
Change From Baseline in 36 Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 16

Arms and interventions

Arm 1: PlaceboPlacebo comparator

Participants will receive matching placebo to JNJ-88545223, from Week 0 to Week 16.

Arm 2: JNJ-88545223 Dose 1Experimental

Participants will receive JNJ-88545223 Dose 1 from Week 0 to Week 16.

Arm 3: JNJ-88545223 Dose 2Experimental

Participants will receive JNJ-88545223 Dose 2 from Week 0 to Week 16.

Arm 4: JNJ-88545223 Dose 3Experimental

Participants will receive JNJ-88545223 Dose 3 from Week 0 to Week 16.

Drugs: JNJ-88545223, Placebo

Sites

75 sites in 8 countries

United States 18, Poland 14, China 10, Germany 9, Hungary 7, Czechia 6, Japan 6, Spain 5